Enhance efficacy, simply and efficiently 

Azymetric™ antibodies possess the desirable drug-like features of naturally occurring antibodies, including:

• Long serum half-life and high stability
• Ability to mediate effector function
• Low immunogenicity risk

Azymetric™ antibodies are compatible with standard manufacturing processes with high yields and purity.

• Use conventional antibody purification and manufacturing processes
• Rapidly screen target and sequence combinations for bispecific activities in the final therapeutic 

The core of the Azymetric™ therapeutic platform consists of proprietary amino acid modifications in the heavy and light chains of an antibody that enable the transformation of monospecific (single target) antibodies into bispecific antibodies, which can simultaneously bind to two distinct locations on a target or two targets.

Azymetric™ antibodies are compatible with glyco-engineering and other Fc modifications, including the EFECT™ Platform, to enhance therapeutic activity. 

Unlike many other bispecific platforms, Azymetric™ enables the generation of fully IgG-like antibodies and is compatible with alternative target binding formats (e.g. Fabs, scFvs, and VHHs) and antibody-drug conjugates.